Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada

Clicks: 219
ID: 269227
2005
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #119 of 1,084 articles by views in clinical infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AbstractBackground. Clinicians who treat patients with Clostridium difficile–associated diarrhea (CDAD) in Quebec, Canada, have noted an apparent increase in th
Reference Key
jacques2005clinicalincreasing Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Pépin, Jacques;Alary, Marie-Eve;Valiquette, Louis;Raiche, Evelyne;Ruel, Joannie;Fulop, Katalin;Godin, Dominique;Bourassa, Claude;
Journal clinical infectious diseases
Year 2005
DOI
DOI not found
URL
http://dx.doi.org/10.1086/430315
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult adolescent aged middle aged Child Infant Recurrence preschool risk factors anti-bacterial agents / therapeutic use metronidazole / therapeutic use vancomycin / therapeutic use enterocolitis treatment failure quebec pmid:15889355 doi:10.1086/430315 jacques pepin marie-eve alary claude bourassa pseudomembranous / drug therapy*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.